Bayer
Whippany
New Jersey
United States
914 articles about Bayer
-
Bayer Opens First Cell Therapy Manufacturing Facility to Advance Regenerative Medicines on a Global Scale
10/10/2023
Bayer AG announced the opening of its first Cell Therapy Launch Facility in Berkeley, California to create the capacity to bring cell therapies to patients on a global scale.
-
Twist Bioscience Enters into Antibody Discovery and Licensing Option Agreement with Bayer of up to $188 Million
10/5/2023
Twist Bioscience Corporation today announced an antibody discovery, option and license agreement with Bayer.
-
The Menopause Society Annual Meeting 2023: Bayer to present latest real-world evidence of menopausal symptoms and their treatment
9/27/2023
Bayer will present the latest RWE research results which focuses on treatment utilization and pathways in women with menopausal symptoms at the upcoming Menopause Society Annual Meeting.
-
Bayer’s Kerendia® (finerenone) Included in Latest Focused Guideline Clinical Updates from European Society of Cardiology
8/31/2023
Bayer’s Kerendia® (finerenone) was included in the European Society of Cardiology’s (ESC) latest clinical guidance for patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).
-
Bayer Expands Clinical Development Program Investigating Finerenone for Potential Treatment of Heart Failure
8/31/2023
Bayer announced it is further investing in MOONRAKER— its clinical development program to investigate Kerendia® (finerenone) as a potential treatment for heart failure (HF) — with the initiation of three additional investigator-sponsored collaborative studies.
-
Pairwise, Bayer Build on Successful Gene Editing Partnership With New Five-Year, Multi-Million Dollar Collaboration to Further Advance Short-Stature Corn
8/29/2023
Pairwise, a food and agriculture company known for bringing the first gene-edited food to the U.S. market, and Bayer announced a new five-year, multi-million Dollar agreement focused on innovations in short-stature corn.
-
BlueRock's Phase I study with bemdaneprocel in patients with Parkinson's disease meets primary endpoint
8/28/2023
Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG, announced details of the positive data from the Phase I clinical trial for bemdaneprocel, a stem cell derived investigational therapy for treating Parkinson's disease.
-
Bayer: How Innovative Farmers Are Tailoring Their Crop Protection
8/24/2023
When it comes to raising crops, protecting them through harvest is often the toughest part of the job.
-
Mahana Therapeutics Signs Agreement with Consumer Health Division of Bayer to Commercialize Digital Therapeutics
8/22/2023
Mahana Therapeutics, a leading provider of prescription digital therapeutics, announced that the company has entered into a multi-million-dollar distribution and marketing partnership with the Consumer Health division of Bayer to commercialize digital therapeutics.
-
NorthStar Medical Radioisotopes Executes Supply Agreement with Bayer for Therapeutic Radioisotope Actinium-225 (Ac-225)
7/18/2023
NorthStar Medical Radioisotopes today announced the signing of a supply agreement for the therapeutic medical radioisotope, actinium-225 (Ac-225) with Bayer.
-
The Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer, and Merck
7/18/2023
Illumina Inc., a global leader in DNA sequencing and array-based technologies, in collaboration with Nashville Biosciences, LLC, a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center, announced the five founding members of the Alliance for Genomic Discovery.
-
Evotec Receives Milestone Payment for First Patient Dosed in Phase I Study of Bayer Kidney Disease Programme
6/29/2023
Evotec SE announced that it is to receive a € 2 m milestone payment from Bayer AG, which is triggered by the first patient dosed in the clinical Phase I study of a kidney disease programme stemming from the Evotec-Bayer multi-target research collaboration in kidney diseases.
-
Bayer initiates Phase III studies with investigational contrast agent gadoquatrane
6/27/2023
Bayer, a global leader in radiology, has initiated the Phase III clinical development program called QUANTI, aiming to evaluate the safety and efficacy of gadoquatrane, an investigational extracellular macrocyclic gadolinium-based contrast agent (GBCA) for use in magnetic resonance imaging (MRI).
-
FDA approves Bayer’s Ultravist® (iopromide) injection for contrast-enhanced mammography
6/23/2023
Bayer announced today that Ultravist® (iopromide)-300, -370, its iodine-based contrast agent, has been approved by the U.S. Food and Drug Administration (FDA) for contrast-enhanced mammography (CEM) – making it the only contrast agent approved for this indication.
-
Bayer to Investigate Finerenone in Phase III Study in Adults With Chronic Kidney Disease Associated With Type 1 Diabetes
6/22/2023
Bayer announced today the initiation of FINE-ONE, a global, multicenter, randomized, placebo-controlled, double-blind, parallel-group Phase III study to evaluate the efficacy and safety of a new investigational use of finerenone versus placebo in adults with chronic kidney disease (CKD) and type 1 diabetes (T1D).
-
Bayer Announces Senior Bayer Representative and President of Bayer U.S.
6/21/2023
Bayer, one of the country’s leading life-sciences companies, announced its new Senior Bayer Representative and President of Bayer U.S. This press release features multimedia.
-
Bayer Announces Changes to U.S. Country Leadership Team
6/8/2023
Bayer, one of the country’s leading life-sciences companies, announced changes to its U.S. Country Leadership Team.
-
Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncology
6/1/2023
Bayer and Cedilla Therapeutics today announced an exclusive license agreement to develop and commercialize Cedilla Therapeutics’ CyclinE1/CDK2 complex inhibitors which selectively address oncogenic drivers.
-
Bayer Presents New Data Across Oncology Portfolio at the 2023 ASCO Annual Meeting
5/25/2023
Bayer will highlight scientific research in oncology at the 2023 American Society of Clinical Oncology Annual Meeting, taking place from June 2-6, 2023.
-
Bayer’s Grants4Ag Program Awards 21 Crop Science Research Grants for 2023
5/24/2023
Bayer announced its 2023 cohort of Grants4Ag grant recipients who have been selected to research promising sustainability and biotechnology subjects in agriculture with support from Bayer.